{"disease":{"id":"hereditary-inclusion-body-myopathy-hibm","name":"hereditary inclusion body myopathy hibm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01830972","title":"An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT01634750","title":"Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT04671472","title":"Efficacy Confirmation Study of NPC-09","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Nobelpharma","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}